Shares of Protagonist Therapeutics Inc (NASDAQ:PTGX) have received a consensus rating of “Hold” from the six research firms that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $37.00.
Several research analysts recently commented on the stock. BMO Capital Markets increased their target price on shares of Protagonist Therapeutics from $40.00 to $43.00 and gave the stock an “outperform” rating in a report on Tuesday, November 7th. Zacks Investment Research cut shares of Protagonist Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 4th. BidaskClub cut shares of Protagonist Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, January 19th. Finally, Stifel Nicolaus assumed coverage on shares of Protagonist Therapeutics in a report on Monday, January 29th. They set a “buy” rating and a $32.00 target price for the company.
Shares of Protagonist Therapeutics (NASDAQ PTGX) traded down $0.11 on Friday, reaching $16.95. 122,708 shares of the company traded hands, compared to its average volume of 111,383. Protagonist Therapeutics has a fifty-two week low of $8.00 and a fifty-two week high of $23.75. The firm has a market capitalization of $353.27, a PE ratio of -6.30 and a beta of -0.80.
A number of hedge funds have recently made changes to their positions in the business. Millennium Management LLC lifted its stake in Protagonist Therapeutics by 40.3% in the fourth quarter. Millennium Management LLC now owns 192,730 shares of the company’s stock valued at $4,009,000 after acquiring an additional 55,378 shares during the last quarter. TIAA CREF Investment Management LLC lifted its stake in Protagonist Therapeutics by 38.4% in the fourth quarter. TIAA CREF Investment Management LLC now owns 32,534 shares of the company’s stock valued at $677,000 after acquiring an additional 9,026 shares during the last quarter. Teachers Advisors LLC lifted its stake in Protagonist Therapeutics by 33.1% in the fourth quarter. Teachers Advisors LLC now owns 21,593 shares of the company’s stock valued at $449,000 after acquiring an additional 5,375 shares during the last quarter. Two Sigma Investments LP acquired a new stake in Protagonist Therapeutics in the fourth quarter valued at $1,202,000. Finally, Two Sigma Advisers LP acquired a new stake in Protagonist Therapeutics in the fourth quarter valued at $362,000. Hedge funds and other institutional investors own 47.54% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Protagonist Therapeutics Inc (PTGX) Receives $37.00 Consensus Target Price from Analysts” was posted by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://www.tickerreport.com/banking-finance/3229172/protagonist-therapeutics-inc-ptgx-receives-37-00-consensus-target-price-from-analysts.html.
Protagonist Therapeutics Company Profile
Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.